Ares Capital Stock Forecast, Price & News

Ares Capital (NASDAQ:ARCC) Frequently Asked Questions

Is Ares Capital a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ares Capital in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ares Capital stock.
View analyst ratings for Ares Capital or view top-rated stocks.

How has Ares Capital's stock been impacted by COVID-19 (Coronavirus)?

Ares Capital's stock was trading at $15.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARCC stock has increased by 34.6% and is now trading at $21.40.
View which stocks have been most impacted by COVID-19.

Are investors shorting Ares Capital?

Ares Capital saw a increase in short interest in December. As of December 31st, there was short interest totaling 10,140,000 shares, an increase of 16.3% from the December 15th total of 8,720,000 shares. Based on an average daily volume of 2,360,000 shares, the short-interest ratio is currently 4.3 days.
View Ares Capital's Short Interest.

When is Ares Capital's next earnings date?

Ares Capital is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Ares Capital.

How can I listen to Ares Capital's earnings call?

Ares Capital will be holding an earnings conference call on Wednesday, February 9th at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "10162158".

How were Ares Capital's earnings last quarter?

Ares Capital Co. (NASDAQ:ARCC) posted its earnings results on Monday, October, 25th. The investment management company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.45 by $0.02. The investment management company earned $442 million during the quarter, compared to analysts' expectations of $431.01 million. Ares Capital had a trailing twelve-month return on equity of 10.96% and a net margin of 90.29%. During the same quarter in the prior year, the firm posted $0.39 EPS.
View Ares Capital's earnings history.

How often does Ares Capital pay dividends? What is the dividend yield for Ares Capital?

Ares Capital announced a quarterly dividend on Tuesday, October 26th. Investors of record on Wednesday, December 15th will be given a dividend of $0.41 per share on Thursday, December 30th. This represents a $1.64 annualized dividend and a yield of 7.66%. The ex-dividend date is Tuesday, December 14th.
View Ares Capital's dividend history.

Is Ares Capital a good dividend stock?

Ares Capital pays an annual dividend of $1.64 per share and currently has a dividend yield of 7.66%. ARCC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Ares Capital does not yet have a strong track record of dividend growth. The dividend payout ratio of Ares Capital is 45.81%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, Ares Capital will have a dividend payout ratio of 89.13% in the coming year. This indicates that Ares Capital may not be able to sustain their current dividend.
View Ares Capital's dividend history.

What price target have analysts set for ARCC?

7 equities research analysts have issued 1 year target prices for Ares Capital's stock. Their forecasts range from $19.00 to $23.00. On average, they anticipate Ares Capital's stock price to reach $21.68 in the next twelve months. This suggests a possible upside of 1.3% from the stock's current price.
View analysts' price targets for Ares Capital or view top-rated stocks among Wall Street analysts.

Who are Ares Capital's key executives?

Ares Capital's management team includes the following people:

• Michael J. Arougheti, Co-Chairman & Executive Vice President
• Kipp deVeer, Chief Executive Officer & Director
• Mitch Goldstein, Co-President
• Michael Lewis Smith, Co-President
• Penni Roll, Chief Financial Officer

Who are some of Ares Capital's key competitors?

Some companies that are related to Ares Capital include BlackRock (BLK), Bank of New York Mellon (BK), T. Rowe Price Group (TROW), Ameriprise Financial (AMP), State Street (STT), Northern Trust (NTRS), Franklin Resources (BEN), Invesco (IVZ), SEI Investments (SEIC), Affiliated Managers Group (AMG), Cohen & Steers (CNS), Prospect Capital (PSEC), Main Street Capital (MAIN), Golub Capital BDC (GBDC) and Virtus Investment Partners (VRTS).
View all of ARCC's competitors.

What other stocks do shareholders of Ares Capital own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ares Capital investors own include AT&T (T), Enterprise Products Partners (EPD), Energy Transfer (ET), Annaly Capital Management (NLY), AGNC Investment (AGNC), New Residential Investment (NRZ), AbbVie (ABBV), Cisco Systems (CSCO), Main Street Capital (MAIN) and Verizon Communications (VZ).

What is Ares Capital's stock symbol?

Ares Capital trades on the NASDAQ under the ticker symbol "ARCC."

Who are Ares Capital's major shareholders?

Ares Capital's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Confluence Investment Management LLC (0.94%), Sound Income Strategies LLC (0.36%), Gilbert & Cook Inc. (0.28%), LGT Capital Partners LTD. (0.12%), Joel Isaacson & Co. LLC (0.03%) and Stratos Wealth Partners LTD. (0.03%). Company insiders that own Ares Capital stock include Joshua M Bloomstein, Michael J Arougheti, Michael K Parks, Michael Lewis Smith, Penelope F Roll, R Kipp Deveer, Robert L Rosen and Steven B Mckeever.
View institutional ownership trends for Ares Capital.

Which major investors are selling Ares Capital stock?

ARCC stock was sold by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD., Monument Capital Management, Onyx Bridge Wealth Group LLC, Atlantic Union Bankshares Corp, RVW Wealth LLC, Summit X LLC, and Capital Investment Advisors LLC.
View insider buying and selling activity for Ares Capital or view top insider-selling stocks.

Which major investors are buying Ares Capital stock?

ARCC stock was bought by a variety of institutional investors in the last quarter, including Gilbert & Cook Inc., Joel Isaacson & Co. LLC, Stratos Wealth Partners LTD., Sound Income Strategies LLC, Latitude Advisors LLC, Confluence Investment Management LLC, Hollencrest Capital Management, and Financial Management Network Inc.. Company insiders that have bought Ares Capital stock in the last two years include Joshua M Bloomstein, Michael J Arougheti, Michael K Parks, Michael Lewis Smith, Penelope F Roll, R Kipp Deveer, Robert L Rosen, and Steven B Mckeever.
View insider buying and selling activity for Ares Capital or or view top insider-buying stocks.

How do I buy shares of Ares Capital?

Shares of ARCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ares Capital's stock price today?

One share of ARCC stock can currently be purchased for approximately $21.40.

How much money does Ares Capital make?

Ares Capital has a market capitalization of $9.86 billion and generates $1.51 billion in revenue each year. The investment management company earns $484 million in net income (profit) each year or $3.58 on an earnings per share basis.

When was Ares Capital founded?

Ares Capital was founded in 2004.

What is Ares Capital's official website?

The official website for Ares Capital is www.arescapitalcorp.com.

Where are Ares Capital's headquarters?

Ares Capital is headquartered at 245 PARK AVENUE 44TH FLOOR, NEW YORK NY, 10167.

How can I contact Ares Capital?

Ares Capital's mailing address is 245 PARK AVENUE 44TH FLOOR, NEW YORK NY, 10167. The investment management company can be reached via phone at (212) 750-7300, via email at [email protected], or via fax at 212-750-1777.